Antisoma (LSE: ASM.L - news) shares could double if the ovarian cancer drug, R1549, is successful, and halve if it is not says the Independent. Given the probability of success, reckoned to be about 65%, that looks a gamble worth taking says the paper.

London, UK, and Boston, MA: 16 May 2008 Cancer-focused biotechnology
company Antisoma plc (LSE: ASM; US OTC: ATSMY) today announces that
it has entered into an agreement to acquire private US oncology
company Xanthus Pharmaceuticals, Inc. in an all-share deal valued at
GBP 26.8 million (USD 52.2 million). Simultaneously, Antisoma has
executed a fundraising that will provide an additional GBP 20.9
million before expenses to the Enlarged Group.

http://moneyam.uk-wire.com/cgi-bin/articles/20080516080900H0000.html

Antisoma now gaining critical mass in its field, looking very good for the future now.

what on earth happened today??

Dread to think! Luckily don't hold currently but this has been a promising-looking company. AZM looked as though it might follow at one point, but then regained its composure somewhat

Been holding since before Christmas and will continue to hold, so much going with ASM, it seems to move around from 22p-28p at moment but no apparent reason for fall today, very strange.

Particularly strange in view of today's news:

"London, UK, 29 May 2008 - Antisoma (LSE:ASM; USOTC:ATSMY) announces
that it has received a milestone payment of USD 25 million from
Novartis. This was triggered by the recent initiation of a phase III
trial of ASA404 in non-small cell lung cancer."

I thought I was the only one here more the merrier.

London, UK, 30 May 2008 - Antisoma (LSE:ASM; USOTC:ATSMY) announces
today details of two presentations on ASA404 that will be made at the
upcoming 2008 Annual Meeting of the American Society of Clinical
Oncology (ASCO):

Abstract no. 8072 (poster) Comparison of safety and efficacy between
squamous and non-squamous non-small cell lung cancer (NSCLC) patients
in phase II studies of DMXAA (ASA404); M. J. McKeage, M. B. Jameson,
AS1404-201 Study Group Investigators; on Sunday 1 June, 2-6pm - Board
45c, in S Hall A1.

Abstract no. 5007 (oral presentation) Addition of DMXAA (ASA404) to
docetaxel in patients with hormone-refractory metastatic prostate
cancer (HRMPC): update from a randomized, phase II study; R. Pili, M.
Rosenthal, AS1404-203 study group investigators; on Monday 2 June,
11.30-11.45am in Clinical Science Symposium on 'Novel antiangiogenic
mechanisms' in Room W375a.

Investor`s Chronicle - 2 June 2008

Antisoma announced that it has further data supporting its lung cancer treatment in an indication that represents just under half of sufferers, giving it a big competitive edge over the existing lung cancer treatment, Genentech's Avastin.
Lung cancer is the most common cause of cancer-related death in men and the second most common in women, and is responsible for about 1.3 million deaths annually. Antisoma is developing a lung cancer vaccine alongside partner Novartis that treats both squamous and non-squamous indications. In contrast, Genentech's Avastin only treats less severe non-squamous sufferers, who represent just over half of all sufferers.

Antisoma's shares rose just over 6 per cent to 23p in response to the positive
news, but it has been a bumpy ride; its shares have more than halved in the past 12 months.

In a rare move in the depressed UK biotech sector, two weeks ago Antisoma announced the 27m share based acquisition of US late stage vaccine developer Xanthus. KBC Peel Hunt analyst, Paul Cuddon, said that the transaction was "very positive" for Antisoma because of the strength of Xanthus' portfolio, with one drug at the marketing approval stage by the US Food and Drug Administration. He increased his valuation from 40p to 46p.


SHARE TIP UPDATE :

We advised buying Antisoma shares at 27p (11 April 2008). Antisoma still has high cash holdings, and with the result of its leukaemia treatment (AS1411) trial also due this quarter, we maintain our buy recommendation.

Antisoma plc

Directors' Share Dealing

9 June 2008, London, UK: Antisoma plc ("Antisoma" or the "Company")
(LSE: ASM; USOTC: ATSMY), the cancer drug developer, announces that
both Dr Barry Price, Chairman and Glyn Edwards, CEO, have purchased
ordinary shares of 1p each in the Company as follows:


+------------------------------------------------------------------------+
|Director |Date of |Amount |Price |Total amount |% of Company |
| |transaction |of shares |(p) |of |held |
| | |purchased | |shares held |following the|
| | | | |in the |transaction |
| | | | |Company | |
| | | | |following | |
| | | | |the | |
| | | | |transaction | |
|----------+-------------+-----------+-------+-------------+-------------|
|Dr Barry |06.06.2008 |100,000 |22.25 |743,077 |0.17% |
|Price | | | | | |
| | | | | | |
|----------+-------------+-----------+-------+-------------+-------------|
|Glyn |06.06.2008 |470,000 |21.25 |2,140,000 |0.48% |
|Edwards | | | | | |
+------------------------------------------------------------------------+

Have actually got back into this - looking good again.

Out of these and into SKP